Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD

Official title

Lentiviral Vector-modified Autologous Hematopoietic Stem Cells for Metachromatic Leukodystrophy (MLD)

Overview

This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to transduce patient-derived hematopoietic stem cells (HSCs), with the goal of achieving therapeutic gene correction through transplantation of genetically modified HSCs. The primary objectives are to evaluate the safety and efficacy of the gene therapy clinical protocol.

Detailed description

Metachromatic leukodystrophy (MLD) is a rare lysosomal storage disease. This disease is an inherited single gene autosomal recessive defect. MLD is caused by a mutation in the ARSA gene encoding arylsulfatase A which leads to a deficiency in sulfatide degradation, resulting in its accumulation in oligodendrocytes, Schwann cells and neurons. A critical level of sulfatide storage can trigger demyelination, the hallmark of MLD, which results in multiple neurological symptoms. MLD has different onset ages including late infancy (1-2 years), adolescence (4 years-before sexual maturity) and adulthood (after sexual maturity). MLD patients are normally rescued by hematopoietic stem cell transplantation (HSCT) from a matched healthy donor. However, HSCT must be performed at a very early stage of the disease and carries a significant risk of graft-versus-host disease (GVHD), which restricts its therapeutic opportunities in MLD patients. This trial aims to treat MLD using an improved self-inactivating lentiviral vector (LV) carrying a functional ARSA gene to transduce patient-derived HSCs in culture, then delivering these genetically corrected HSCs carrying the normal ARSA gene to correct the genetic defect. The primary objectives are to evaluate the safety of the improved LV TYF-ARSA and the clinical protocol for gene therapy using the genetically modified HSCs, and the therapeutic efficacy in patients after treatment, assessment of vector integration sites, and finally the long-term correction of the pathological symptoms.

Interventions

• Genetic Lentiviral TYF-ARSA correction of patient's autologous HSCs
  Infusion of lentiviral TYF-ARSA modified autologous HSCs at 1\~10x10\^6 gene-modified cells per kg body weight.

Primary outcome measures

• Safety of auto-HSCs transduced with lentiviral TYF-ARSA [Time frame: up to 1 year follow up]
• Altered disease progression [Time frame: up to 3 year follow up after treatment]]
• Altered disease progression [Time frame: up to 3 year follow up after treatment]]

Eligibility criteria

Inclusion criteria

• age >= 1 month
• ARSA gene sequence analysis to confirm MLD mutations
• Brain MR Imaging
• Parent / guardian / patient signing informed consent
• Patients and their families have a strong willingness to participate in clinical trials, are willing to bear all the consequences caused by the failure of the trial, and sign the informed consent

Exclusion criteria

• HIV positive
• Experiencing uncontrolled viral, bacterial or fungal infections, malignant tumors, heart abnormalities, liver dysfunction, or renal insufficiency
• Cannot perform an MRI
• Infection or dermatosis at infusion site
• Any condition that may increase the subject's risk or interfere with the results of the trial, e.g. in addition to MLD, there are other neurological disorders.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Shenzhen Geno-Immune Medical Institute — Shenzhen

Identifiers

NCT: NCT07046338 · GIMI-IRB-25001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗